Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET

Company Participants

Jenny Kobin - Investor Relations

George Lasezkay - President and Chief Executive Officer

Thomas Ciulla - Chief Medical Officer and Chief Development Officer

Charles Deignan - Chief Financial Officer

Conference Call Participants

Zegbeh Jallah - ROTH Capital Partners

Jonathan Wolleben - JMP Securities

Yi Chen - H.C. Wainwright

Serge Belanger - Needham

Julian Harrison - BTIG

Operator

Good day and thank you for standing by. Welcome to the Clearside Biomedical First Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-Answer session. [Operator Instructions]

Now, it is my pleasure to hand the conference over to your first speaker today, Jenny Kobin, Clearside Investor Relations. Thank you, please go ahead.

Jenny Kobin

Good afternoon everyone and thank you for joining us on the call today. Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the Company's future expectations, plans and prospects, constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2021, and our other SEC filings available on our website.

In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.

On today's call, we have George Lasezkay, our Chief Executive Officer; Dr. Thomas Ciulla, our Chief Medical Officer and Chief Development Officer; and Charlie Deignan, our Chief Financial Officer. After our formal remarks, we will open the call for your questions.

I would now like to turn the call over to George.

George Lasezkay

Thank you, Jenny. We continued to make steady progress in 2022. In March we were pleased that Bausch + Lomb announced their U.S. launch of XIPERE in the United States as the first therapy approved for macular edema associated with uveitis, a potentially blinding. Ahead of the official launch, Bausch worked closely with 100s of retinal specialists throughout the country, to train them on the use of our SCS Microinjector and to build interest in using XIPERE to treat the uvitic macular edema patients.